“Behavioral/Mental Health Care Software & Services Market Report is set to have rapid growth due the increasing adoption of BHS, availability of government funding, and government initiatives to encourage EHR adoption in behavioral health organizations at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Behavioral/Mental Health Care Software & Services Market Forecast 2019-2029: By Component, By Delivery Model, By Function, By End Use, By Region, And Segment Forecasts

The global Behavioral/Mental Health Care Software & Services market is poised for rapid growth between 2019 and 2029. The market is likely to experience growth opportunities in software behavioral health in emerging markets and a growing emphasis on subscription models.

In 2014, approximately 21.5 million people in the United States were affected by substance abuse disorders. Of these, only 2.5 million people have actually received treatment. Therefore, there is a large margin for improving the performance of behavioral health care. According to the US Department of Health and Human Services, the health budget for substance abuse treatment services was estimated at around $ 35 billion in 2014.

With the increasing burden of depression and stress due to working or personal life, the adoption rate of an EHR system is increasing. It has also been noted that over time, specialized healthcare providers, including mental and behavioral health providers, have begun to request electronic medical records (EHRs) that have been designed specifically for their needs.

Leading companies featured in the report include Cerner Corporation; Core solutions, Inc.; Epic; Netsmart Technologies; Welligent, Inc.; and others

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever